All Articles PartnerRe Perspectives Previous Article

A New Dawn for Diabetes Management Reference List

Full reference list for the 2022 PartnerRe article: “A New Dawn for Diabetes Management”

  1. The ACCORD study group. Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. N Engl J Med 2011; 364:818-828. DOI: 10.1056/NEJMoa1006524
  2. American Diabetes Association; Standards of Medical Care in Diabetes—2022Abridged for Primary Care Providers. Clin Diabetes 1 January 2022; 40 (1): 10–38.
  3. Ahmad T. et al: A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease, European Cardiology Review 2021;16:e11.
  4. Anker S.D. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385:1451-1461. DOI: 10.1056/NEJMoa2107038
  5. Begic E. et al. Diabetes: total risk – benefit of SGLT2 inhibitors and GLP1 agonists. ESC e-Journal of Cardiology Practice Volume 22 2022 v 22, N° 9 – 20 Apr 2022.
  6. Bonora B.M. et al. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovasc Diabetol 20, 39 (2021).
  7. Brannick B. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 2016 Jun;241(12):1323-31. doi: 10.1177/1535370216654227.
  8. Braunwald E. SGLT2 inhibitors: the statins of the 21st century. Eur Heart J. 2022 Mar 14;43(11):1029-1030. doi: 10.1093/eurheartj/ehab765
  9. Burrow N.R. et al. Declining Rates of Hospitalization for Selected Cardiovascular Disease Conditions Among Adults Aged ≥35 Years with Diagnosed Diabetes, U.S., 1998–2014. Diabetes Care2018;41(2):293–302.
  10.  Brown E. et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet 2021; 398: 262–76.
  11. Ceriello A. Glucose Variability and Diabetic Complications: Is It Time to Treat? Diabetes Care 1 June 2020; 43 (6): 1169–1171.
  12. Ceriello A. Glycaemic management in diabetes: old and new approaches. Lancet. Vol 10, issue 1. P75-84, January 01, 2022. 
  13. Ceriello A. et al. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol 2019;7: 221–230. doi: 10.1016/S2213-8587(18)30136-0
  14. Ceriello A. et al. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol 20, 218 (2021).
  15. Chow E. et al. The emerging role of incretins and twincretins. Nature Reviews. Endocrinology. Vol 18. P 73-74.
  16. Chow E. et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 63.5 (2014): 1738-1747.
  17. Chung W.K. et al. Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020 Jul;43(7):1617-1635. doi: 10.2337/dci20-0022
  18. Dandona et al. Proinflammatory and Prothrombotic Effects of Hypoglycemia. Diabetes Care. 2010 Jul; 33(7): 1686–1687. https://doi:2337/dc10-0503.
  19. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. Diabetes Care. 1987 Jan-Feb;10(1):1-19. doi: 10.2337/diacare.10.1.1
  20. The emerging risk factor collaboration. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. N Engl J Med 2011; 364:829-841. DOI: 10.1056/NEJMoa1008862
  21. “Diabetes, Now for the Good News”. PartnerRe (2020).
  22. Frias J.P. et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. DOI: 10.1056/NEJMoa2107519
  23. Gregg E.W. et al. Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Diabetes Care 1 September 2021; 44 (9):1916­–1923.
  24. Grisanti L.A. Diabetes and Arrhythmias, Physiol., 26 November 2018. Sec.Cardiac Electrophysiology.
  25. Holman R.R. et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. Engl J Med 2008; 359:1577-1589. DOI: 10.1056/NEJMoa0806470
  26. International Diabetes Federation (IDF) Diabetes Atlas.
  27. Inzucchi S.E et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care 44.2 (2021): 586-594.
  28. Jia G. et al. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018 Feb 16;122(4):624-638. doi: 10.1161/CIRCRESAHA.117.311586
  29. Joseph J.J. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart  Circulation2022;145:e722–e759. DOI: 10.1161/CIR.0000000000001040
  30. McGuire D.K. et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol.2021;6(2):148–158. doi:10.1001/jamacardio.2020.4511
  31. Müller T.D. et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21, 201–223 (2022).
  32. Nair A.T.N. et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med 28, 982–988 (2022).
  33. Pearson-Stuttard J. et al. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003-2018: an epidemiological analysis of linked primary care records.
  34. Perkovic A. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295-2306. DOI: 10.1056/NEJMoa1811744
  35. Raghavan S. et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019 Feb 19;8(4):e011295. doi: 10.1161/JAHA.118.011295
  36. Rathmann W. et al. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia 65, 949–954 (2022).
  37. Rawshani A. et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2018; 379:633-644. DOI: 10.1056/NEJMoa1800256
  38. Relationship between Diabetes and COVID-19. Diabetes Canada.
  39. Rosenstock J. et al; Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet, 2021 Jul 10;398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6
  40. Sattar N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. doi: 10.1016/S2213-8587(21)00203-5. Epub 2021 Aug 20.
  41. Shorikov E.I. et al: Phenotypes of arterial hypertension in patients with diabetes mellitus type 2: orthostatic hypotension and daily variability of blood pressure. ESC e-Journal of Cardiology Practice. Vol. 22, N° 14 – 01 Jun 2022.
  42. Tomic D. The burden and risks of emerging complications of diabetes mellitus. Nature reviews. Endocrinology. 2022 Jun. DOI: 10.1038/s41574-022-00690-7
  43. Wander P.L. et al. The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection. Diabetes Care2022;45(4):782–788.
  44. Wilding J.P.H. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384:989-1002. DOI: 10.1056/NEJMoa2032183
  45. Xie Y, Ziyad et al. Risks and burdens of incident diabetes in long COVID: a cohort study – The Lancet Diabetes & Endocrinology. DOI:
  46. Zannad F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9
  47. Zelniker T.A. et al. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. doi: 10.1016/j.jacc.2019.11.031. Erratum in: J Am Coll Cardiol. 2020 Sep 22;76(12):1505.
  48. Zinman et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.
  49. Zoler M.L. Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes. Medscape Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes (
  50. Riddle M.C. et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 2021;44:2438–2444.
Get in touch